Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actinogen, Biomarin, Clover, Codagenix, Exscientia, Freeline, Genexine, Huyabio, Puretech, Soleno, Treadwell, Zhimeng.

Up to now, the Pfizer Inc.-Biontech SE COVID-19 vaccine has had a lock on the U.S. pediatric market, for ages 5 to 17, but that could change as early as next week.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amarin, Amivas, Amylyx, Beigene, Bluebird, Guerbet, Homology, Ionis, Mallinckrodt, Merck & Co., Novavax, Nrx, Relief, Veralox.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Atyr, AVM, Bavarian, Orion, Sarepta, Sirona, Umoja, Valneva.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Algernon, Altamira, Biohaven, Biorestorative, Bridgebio, Curocell, Cytokinetics, Daiichi, Day One, Dermata, Dompe, G1, Inhibikase, Kangpu, Optinose, Plus, Promore, Regulus, Revelation, Sanofi, Scancell, Selecta, Surrozen, Veralox.

A lot of eyes are on the World Trade Organization (WTO) Ministerial Conference taking place in Geneva June 12-15, as member countries try to reach a consensus on a proposal that would allow certain members to waive intellectual property (IP) rights on COVID-19 vaccines for at least three to five years.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 4basebio, Anpac Bio-Medical Science, Bavarian Nordic, Chromadex, Critical Path Institute, Cyanvac, Eleusis, Frederick Gardner Cottrell Foundation, Genmab, Gritstone, Halozyme, Janssen, Kinarus, Perfect Holding, Silver Spike.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adverum, Alnylam, Aptevo, Brii, Cend, Fusion, Immunome, Lyndra, Olema, Takeda, Tryp, Verona, Zhittya.